MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-06-2025
Pacira BioSciences Depreciation & Amortization 2011-2025 | PCRX
Annual Depreciation & Amortization Pacira BioSciences
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 78.8 M | 75.6 M | 91.5 M | 28.5 M | 19.9 M | 19.6 M | 13.2 M | 13.8 M | 12.9 M | 11.5 M | 10 M | 5.75 M | 5.65 M | 4.31 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 91.5 M | 4.31 M | 27.9 M |
Quarterly Depreciation & Amortization Pacira BioSciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.9 M | 13 M | 21.2 M | - | 6 M | 4.5 M | 18.4 M | - | 4.1 M | 4.7 M | 19.6 M | - | 5.8 M | 6.5 M | 20 M | - | 15.5 M | 2.9 M | 4.85 M | - | 14.8 M | 9.81 M | 4.82 M | - | 14.5 M | 8.88 M | 3.6 M | - | 9.11 M | 5.61 M | 2.76 M | - | 10.2 M | 6.81 M | 3.1 M | - | 9.66 M | 6.38 M | 3.16 M | - | 8.36 M | 5.53 M | 2.74 M | 10 M | 7.33 M | 4.94 M | 2.6 M | - | 4.05 M | 2.72 M | 1.43 M | - | 4.2 M | - | 1.38 M | - | 400 K | 400 K | 990 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 21.2 M | 400 K | 7.21 M |
Depreciation & Amortization of other stocks in the Drug manufacturers industry
| Issuer | Depreciation & Amortization | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alimera Sciences
ALIM
|
8.75 M | - | - | $ 142 M |  USA |
 |
Assertio Holdings
ASRT
|
28.2 M | $ 0.73 | -3.6 % | $ 51.9 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
6.4 M | - | - | $ 754 M | USA |
 |
Canopy Growth Corporation
CGC
|
21.5 M | $ 1.7 | -2.59 % | $ 183 M |  Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
311 K | - | 7.5 % | $ 6.35 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
1.48 M | - | 0.86 % | $ 117 M | USA |
 |
Agile Therapeutics
AGRX
|
102 K | - | 10.11 % | $ 58.2 M | USA |
 |
Catalent
CTLT
|
489 M | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
31 K | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
646 K | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
306 M | - | - | $ 28.9 M |  Irlanda |
 |
Emergent BioSolutions
EBS
|
125 M | $ 12.37 | 8.32 % | $ 633 M | USA |
 |
Athenex
ATNX
|
4.47 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
2.68 M | $ 21.43 | 0.3 % | $ 2.04 B |  France |
 |
Evolus
EOLS
|
5.3 M | $ 7.18 | 1.99 % | $ 445 M | USA |
 |
Harrow Health
HROW
|
1.06 M | $ 46.29 | -1.64 % | $ 1.51 B | USA |
 |
China Pharma Holdings
CPHI
|
2.62 M | $ 1.53 | -1.92 % | $ 26.7 M |  China |
 |
Bausch Health Companies
BHC
|
1.26 B | $ 6.9 | -0.36 % | $ 2.52 B | Canada |
 |
Organogenesis Holdings
ORGO
|
13.6 M | $ 4.78 | -0.83 % | $ 629 M | USA |
 |
Lannett Company
LCI
|
34.3 M | - | 1.15 % | $ 7.11 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
4.9 M | $ 3.11 | 22.92 % | $ 43.7 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
3.26 M | - | - | $ 193 M | Canada |
 |
Rockwell Medical
RMTI
|
1.44 M | $ 0.88 | -5.3 % | $ 20.5 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
138 K | $ 3.55 | -1.11 % | $ 4.41 M | USA |
 |
Solid Biosciences
SLDB
|
2.46 M | $ 5.75 | -2.04 % | $ 235 M | USA |
 |
PetIQ
PETQ
|
44.5 M | - | 1.64 % | $ 400 M | USA |
 |
Relmada Therapeutics
RLMD
|
1.26 K | $ 4.34 | 6.91 % | $ 131 M | USA |
 |
Jupiter Wellness
JUPW
|
429 K | - | - | $ 33.6 M | USA |
 |
Perrigo Company plc
PRGO
|
326 M | $ 12.77 | -2.78 % | $ 1.75 B | USA |
 |
ProPhase Labs
PRPH
|
4.72 M | $ 0.11 | -0.35 % | $ 1.74 M | USA |
 |
Radius Health
RDUS
|
1.16 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
8.22 M | - | -4.76 % | $ 65.3 M | USA |
 |
Veru
VERU
|
268 K | $ 2.4 | -0.83 % | $ 324 M | USA |
 |
OptiNose
OPTN
|
402 K | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
116 K | - | -27.8 % | $ 2.56 M | USA |
 |
cbdMD
YCBD
|
452 K | $ 1.19 | -0.83 % | $ 5.13 M | USA |
 |
SCYNEXIS
SCYX
|
580 K | $ 0.64 | -0.91 % | $ 30.6 M | USA |
 |
Tricida
TCDA
|
442 K | - | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
35.7 M | $ 11.01 | -9.4 % | $ 6.8 B | Canada |
 |
TherapeuticsMD
TXMD
|
922 K | $ 1.7 | -2.86 % | $ 17.7 M | USA |
 |
Zomedica Corp.
ZOM
|
830 K | - | -0.21 % | $ 98 M | USA |
 |
Viatris
VTRS
|
3.03 B | $ 11.68 | 0.29 % | $ 14.2 B | USA |